全部分类
  • RM-018
RM-018的可视化放大

RM-018

RM-018 是一种 KRASG12C 活性状态的抑制剂。RM-018 保留了结合和抑制 KRASG12C/Y96D 的能力。RM-018 与 GTP-bound 结合,激活 KRASG12C 的 [RAS(ON)] 状态。

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

RM-018的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 5mg
    ¥15487.00
    12390.00
    - +
  • 10mg
    ¥25112.00
    20090.00
    - +
  • 25mg
    ¥51300.00
    41040.00
    - +
  • 50mg
    ¥80150.00
    64120.00
    - +
  • 100mg
    ¥126112.00
    100890.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajcx35924
  • CAS: 2641993-55-5
  • 别名:
  • 分子式: C56H72N8O8
  • 分子量: 985.22
  • 纯度: >98%
  • 溶解度:
  • 储存: Store at -20°C
  • 库存: 现货

Background

RM-018 is a potent, functionally distinct tricomplex KRASG12C active-state inhibitor. RM-018 retains the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. RM-018 binds specifically to the GTP-bound, active ["RAS(ON)"] state of KRASG12C[1].


RM-018 is a "tricomplex" KRAS inhibitor, which exploits a highly abundant chaperone protein, cyclophilin A, to bind and inhibit KRASG12C[1].RM-018 (0.01-1000 nM; 72 hours) has IC50s of 1.4-3.5 nM (KRASG12C) and 2.8-7.3 nM (KRASG12C/Y96D) in NCI-H358, MIA PaCa-2, Ba/F3, and MGH1138-1 cells[1].RM-018 (0-100 nM; 4 hours) inhibits the expression of KRAS, pERK, and pRSK protein[1].


[1]. Tanaka N, et.al. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021 Aug;11(8):1913-1922.

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算